TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Business

    The Dime

    Most cannabis companies won’t survive the next three years. The ones that do will have better capital discipline, sharper regulatory reads, and operational frameworks built for compression, not growth. The Dime is where cannabis operators, executives, and investors hear directly from the CEOs and founders making those decisions right now: MSO strategy, state-by-state market dynamics, cultivation and extraction economics, brand positioning, and the financing structures keeping companies alive. Bryan Fields hosts weekly conversations built for operators, not observers.

    Advertise

    Copyright: © 2023 The Dime

    • Apple Podcasts
    • Google Play
    • Spotify

    Latest Episodes:
    Who Benefits From Federal Cannabis Limbo? ft. Jay Rosenthal Oct 14, 2026
    Show notes

    Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise.

    The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and state regulation collide, the operators built for uncertainty may be the ones hardest to dislodge.

    This week we sit down with Jay Rosenthal

    • Limbo as a moat
    • EU GMP advantage
    • Regulation's hidden winners

    Chapters

    • 00:00 Federal limbo becomes the business model
    • 02:17 The reform everyone agrees on
    • 03:28 Capital markets and the bigger pond
    • 05:35 Six hundred brands and no patience
    • 06:55 Why Rochester can move New York
    • 09:48 Strong operators become obvious
    • 13:40 The cost of crossing state lines
    • 16:28 Aurora Curaleaf and scarce EU GMP assets
    • 20:26 The Canadian future that did not arrive
    • 22:00 What mature industry compliance could bring
    • 24:35 Cultivated's nonsecret sauce
    • 31:41 Cannabis stigma still follows the operator
    • 32:28 Why Cultivated launched membership
    • 40:23 Quality media has a real cost
    • 41:18 California and New York regulators share a market
    • 44:02 Policy goals that fight each other
    • 49:06 Competition cooperation and price compression
    • 52:25 Where to find Jay and Cultivated

    Guest Links

    • Jay Rosenthal - Co-Founder and Managing Director of Cultivated Media
    • Cultivated Media
    • Cultivated events
    • Sign up for the Cultivated Daily newsletter

    Our Links

    • The Dime Podcast — website
    • Bryan Fields on X
    • The Dime on X
    • The Dime on YouTube
    • The Dime on Instagram
    • Newton Insights — insights for extraction teams

    Follow The Dime for more conversations on cannabis business, operations, and international markets.

    Share this episode with an operator rethinking their edibles.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    What Makes Consumers Buy the Same Edible Again? ft. Kim Sanchez Rael Sep 30, 2026
    Show notes

    Fast-acting edibles can command a premium, but labels such as "nano" do not prove the final product works. The larger operating question is whether the formulation improves taste, shelf stability, manufacturing efficiency, and trust at the same time.

    This week we sit down with Kim Sanchez Rael

    Fast onset economics
    The nano problem
    Science/ AI and so much more

    Fast-acting cannabis edibles promise a more predictable experience, but the language on the package does not always tell operators what happens in the final product.

    Kim Sanchez Rael, President and CEO of Azuca, breaks down what "fast" should mean, why slow-onset edibles still dominate, and how formulation choices affect taste, stability, curing time, shelf life, and production efficiency. She explains why "nano" is often a measurement or marketing label rather than proof of a better consumer outcome, then offers four questions brands should ask any infusion supplier.

    The conversation also moves beyond formulation. Kim describes the economics behind fast-acting products, the role of supplier behavior when production is at risk, the case for a single regulatory framework for the cannabis plant, and why operators cannot build a business that depends on an unpredictable regulatory change.

    Topics include:

    • The consumer value of predictable onset
    • Manufacturing tradeoffs in gummy formulation
    • What brands should demand from infusion partners
    • Why structured quality systems matter
    • How Azuca uses AI inside its team and customer experience

    Learn more about Azuca and TiME INFUSION® at https://azuca.co/.

    Guest: Kim Sanchez Rael, President and CEO, Azuca
    Host: Bryan Fields, The Dime

    Chapters

    • 00:01 Why slow-onset edibles still dominate
    • 01:47 The economics of fast acting
    • 03:56 Can brands claim "fast"?
    • 05:56 Predictability and consumer trust
    • 08:06 The retail education gap
    • 10:24 How Azuca licensing works
    • 14:44 Formulation, cannabinoids, and flavor
    • 15:30 When "fast" does not feel fast
    • 18:18 Onset, peak, and duration
    • 20:01 Manufacturing efficiency R&D
    • 23:14 Validating infusion science
    • 24:43 Why "nano" is a buzzword
    • 27:38 The operational cost of change
    • 28:24 Four questions for infusion suppliers
    • 30:00 Supplier behavior as brand experience
    • 32:31 The Fourth of July production rescue
    • 33:48 What cannabis still gets wrong
    • 34:15 The One Plant Solution
    • 37:04 Policy resistance and incrementalism
    • 38:41 AI and "Kimothy"
    • 41:21 Quality systems and sustainable math
    • 44:58 The question Kim wishes people asked
    • 45:45 Where to find Azuca

    Our Links

    • The Dime Podcast — website
    • Bryan Fields on X
    • The Dime on X
    • The Dime on YouTube
    • The Dime on Instagram
    • Eighth Revolution
    • Newton Insights — insights for extraction teams

    Follow The Dime for more conversations on cannabis business, operations, and international markets.

    Share this episode with an operator rethinking their edibles.

    Guest Links

    • Kim Sanchez Rael — Azuca

    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    Europe Is Not a Rescue Plan ft. Jamie Pearson Sep 16, 2026
    Show notes

    Global expansion is often pitched as an opportunity. For an undisciplined cannabis company, it is an expensive way to expose every weakness at once.

    International markets reward specific operating capabilities, not ambition alone. Pharmaceutical standards, reliable supply, disciplined data use, and local market fit determine whether an operator can cross borders without compounding its problems.

    This week we sit down with Jamie Pearson

    • EU GMP's undervalued strategic value
    • Regulation exposes operating weakness
    • Matching strength to global markets

    On The Dime, host Bryan Fields speaks with Jamie L. Pearson, President and Founder of New Holland Group, about European cannabis expansion, medical cannabis supply chains, and building operations that can succeed across borders.

    Key Takeaways

    • Jamie explains why European medical cannabis markets call for pharmaceutical reliability, consistent supply, and a different operating model from adult-use brands.
    • EU GMP (European Union Good Manufacturing Practice) capability can be a strategic asset for cannabis manufacturing and international market entry.
    • Match the company's repeatable strengths to local buyers, regulations, and supply chains before choosing a market.
    • Prove standard operating procedures (SOPs) and quality controls in another U.S. state before adding language, currency, and cross-border complexity.
    • The discussion spans the UK, Germany, Switzerland, Slovenia, Portugal, and Brazil, alongside cannabis data and U.S. hemp regulation.

    Chapters

    00:00 Regulation is breaking the data layer
    02:49 Finding trend data upstream
    06:24 What EU GMP actually demands
    10:19 Why compliant facilities become strategic assets
    16:13 Canada-Europe regulatory harmony
    19:20 Europe is medical first
    25:28 First-mover advantage vs. disciplined execution
    27:59 Medical supply rewards repeatability
    30:48 Weak operations do not travel
    32:24 Switzerland, Slovenia, and Portugal
    35:54 Brazil and partner requirements
    37:07 Practice expansion before global scale
    40:08 The hidden U.S. hemp market
    43:29 Turning customers into political force
    47:10 Directness as respect

    Guest Links

    • Jamie L. Pearson — official bio
    • New Holland Group
    • New Holland Group on LinkedIn

    Related Episode

    Germany Is the Engine: What BAT Knows That Cannabis Doesn't ft. James Yamanaka — continue exploring Germany's cannabis market and operational discipline.

    Our Links

    • The Dime Podcast — website
    • Bryan Fields on X
    • The Dime on X
    • The Dime on YouTube
    • The Dime on Instagram
    • Eighth Revolution
    • Newton Insights — insights for extraction teams

    Follow The Dime for more conversations on cannabis business, operations, and international markets. Share this episode with an operator considering expansion.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    Paige Figi: The Cannabis Industry Is Cheering A Ban On Medicine Aug 04, 2026
    Show notes

    Much of the licensed cannabis industry is quietly counting the volume it expects to inherit from the federal hemp ban coming this November. ** Now December.

    What they may not realize is that the ban could eliminate the full-spectrum therapeutic hemp formulations that helped change America's view of cannabis and are used daily by an estimated 45 million Americans.

    The provision was written by two members of Congress, without a conference or regular order, and inserted into a massive spending bill during the longest government shutdown in American history.

    What should have been handled with a scalpel was done with a sledgehammer.

    This week we sit down with Paige Figi to discuss

    • Silence is a position
    • The scalpel Congress skipped
    • Oval Office, then banned

    Chapters

    00:00 Introduction to the legislative landscape of cannabis

    00:21 The impact of Charlotte's story on cannabis perception

    00:48 Distinguishing hemp from marijuana in legislation

    02:11 The challenges of passing therapeutic hemp laws

    02:52 Congress's need for simple, effective regulation

    03:48 The slow progress of therapeutic hemp legalization

    04:53 The importance of clear plant distinctions

    05:56 The November 12 hemp ban and its implications

    07:02 The dangers of Franken hemp and synthetic cannabinoids

    08:00 The public health emergency posed by recent bans

    08:49 The role of science and data in regulation

    10:13 The importance of industry and public unity

    10:58 How regulations can support medical and adult use

    12:06 The impact of federal bans on patients and consumers

    13:00 The need for a balanced, science-based approach

    14:00 The political landscape and legislative hurdles

    14:53 The power of public advocacy and individual action

    16:07 The future of cannabis regulation and industry alignment

    17:06 How to effectively communicate with policymakers

    18:03 The importance of clear, science-backed legislation

    19:00 The role of the FDA and federal agencies

    20:01 The potential for bipartisan support and progress

    21:08 The significance of the November 12 deadline

    22:06 The ongoing fight for access and regulation

    23:04 The moral and ethical considerations in cannabis policy

    23:49 How consumers can influence policy change

    24:47 The importance of unity within the industry

    25:46 The potential for a balanced, effective regulatory framework

    27:06 The role of science and data in shaping policy

    28:03 The need for responsible, clear regulations

    29:02 The future outlook for therapeutic hemp and CBD

    30:02 Final thoughts and call to action

    Guest Links

    https://www.coalitionforaccess.org/

    https://www.instagram.com/paigefigi/

    https://realmofcaring.org/about/paige-figi/

    Our Links

    Bryan Fields on Twitter

    The Dime on Twitter

    Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.

    At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

    The Dime is a top 5% most shared global podcast

    The Dime is a top 10 Cannabis Podcast

    The Dime has a New Website. Shhhh its not finished.

    🎥 YouTube: The Dime

    📸 Instagram: The Dime

    https://www.newton-insights.com/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    Understand This Before You Use AI To Build Software ft. Chris Guthrie Jul 09, 2026
    Show notes

    AI has made software easier than ever to build. That does not mean every internal tool should become the backbone of your business.

    In this episode, Bryan sits down with Chris Guthrie to break down the growing temptation inside cannabis companies to vibe code internal tools, dashboards, CRMs, ERPs, and operational systems in the name of saving money.

    The problem is not the first version. The problem is what happens two months later, when a field does not map, the workflow breaks, the person who built it is unavailable, and a production team is now relying on code nobody fully understands.

    Chris explains the difference between a useful AI-built prototype and an enterprise-grade system that can survive real operators, messy data, security needs, compliance, multiple departments, M&A diligence, and future FDA-style requirements.

    This conversation covers why descriptive data does not create predictive insight, why Google Sheets to vibe coding can become a path to failure, and why the real AI opportunity starts after the business has clean data, clean processes, and a system strong enough to trust.

    This episode covers:

    • The weekend build that fails
    • Descriptive data will not predict
    • Clean books before M&A

    Chapters

    00:00 The Rise of AI in Software Development

    03:07 Challenges of Internal Software Development

    06:09 Understanding What 'Works' in Software

    09:10 The Risks of Vibe Coding

    12:05 The Importance of Established Infrastructure

    14:58 Cost Considerations in Software Development

    17:56 Predictive Insights and Data Utilization

    21:13 Defining Core Business Focus

    23:17 The Challenges of AI Implementation

    27:00 Understanding AI's Limitations

    28:58 The Importance of Data Governance

    31:11 Navigating Change Management in Cannabis

    35:51 Preparing for Industry Evolution

    40:09 The ROI of ERP Systems

    Our Links:

    Bryan Fields on Twitter

    The Dime on Twitter

    Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.

    At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

    The Dime is a top 5% most shared global podcast

    The Dime is a top 10 Cannabis Podcast

    The Dime has a New Website. Shhhh its not finished.

    🎥 YouTube: The Dime

    📸 Instagram: The Dime

    https://www.newton-insights.com/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    Hirsh Jain: Rescheduling Is Already Picking Winners Jun 25, 2026
    Show notes

    Cannabis rescheduling is not as simple as “Trump rescheduled cannabis.”

    States are interpreting rescheduling completely differently depending on their license structure. These tiny details are widening the gap between potential winners and losers.

    In this episode, we break down what actually changed, what is still unresolved, and why rescheduling may already be picking winners and losers.

    This week, we sit down with Hirsh Jain to discuss:

    • What the April order and June 29 hearing actually mean

    • How the DEA registration portal could impact operators

    • The three pathways for interstate commerce

    • Why state license structure may determine who is positioned for a national market

    Chapters

    00:00 Understanding Cannabis Rescheduling

    02:53 The Implications of Medical vs. Adult Use Cannabis

    05:48 Navigating Federal Legality for Medical Cannabis

    09:03 DEA Registration: A New Era for Cannabis Businesses

    11:53 The Complexities of DEA Registration

    15:02 Interstate Commerce: The Future of Cannabis Trade

    17:46 State Models and Their Impact on Cannabis Regulation

    21:02 Winners and Losers in the Cannabis Market

    24:04 The Role of Politics in Cannabis Regulation

    27:01 The Future of Interstate Commerce in Cannabis

    38:15 Understanding the Dormant Commerce Clause

    40:46 Interstate Commerce and Political Friction

    42:43 Legal Challenges to Cannabis Rescheduling

    44:37 The April Order and Its Implications

    51:05 Upcoming Hearings and Their Significance

    59:22 Emerging Markets in Red States

    01:05:34 Cultural Shifts and Legal Implications

    01:10:16 Looking Ahead: Signals for Progress

    Guest Links:

    https://www.anandastrategy.com/

    Our Links:

    Bryan Fields on Twitter

    The Dime on Twitter

    Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.

    At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

    The Dime is a top 5% most shared global podcast

    The Dime is a top 10 Cannabis Podcast

    The Dime has a New Website. Shhhh its not finished.

    🎥 YouTube: The Dime

    📸 Instagram: The Dime

    https://www.newton-insights.com/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    Germany Is the Engine: What BAT Knows That Cannabis Doesn't ft. James Yamanaka Jun 22, 2026
    Show notes

    Predictable cash flow is the whole game. In cannabis, predictable is the one thing almost nobody has.

    Organigram CEO James Yamanaka came up over 20 years at British American Tobacco, where that discipline is the entire model. He thinks the opportunity starts there: trim the portfolio, stop chasing every trend, tighten the supply chain, lean on the science, and align operations. Germany's market could nearly double in the next two years, but capturing it will take more than expansion.

    This week we sit down with James Yamanaka, CEO of Organigram:

    • A BAT perspective on cannabis
    • Why chasing every trend loses money
    • How the Sanity deal unlocks Germany

    Chapters:

    00:00 Introduction to Organigram and BAT's Involvement

    05:24 Shifting Perspectives: From BAT to Organigram

    09:08 Understanding the Complexity of the Cannabis Market

    13:12 Balancing Listening and Leadership

    17:24 Data-Driven Decision Making in Cannabis

    21:18 Strategic SKU Management and Market Forecasting

    24:17 Leveraging BAT's Expertise in Cannabis

    30:04 The Strategic Importance of the Sanity Deal

    39:57 Navigating Regulatory Challenges in the Cannabis Industry

    Guest Links:

    • https://www.linkedin.com/in/james-yamanaka-aaa32a/
    • https://www.organigram.ca/

    Our Links:

    Bryan Fields on Twitter

    The Dime on Twitter

    Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.

    At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

    The Dime is a top 5% most shared global podcast

    The Dime is a top 10 Cannabis Podcast

    The Dime has a New Website. Shhhh its not finished.

    🎥 YouTube: The Dime

    📸 Instagram: The Dime

    https://www.newton-insights.com/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    Why Ohio Cannabis Is Built Different: Inside the Regulator-Operator Alignment That's Actually Working ft. Caroline Henry Jun 11, 2026
    Show notes

    When a regulator asks what the downside is of adding one more testing requirement, what is the downside? Just a little more safe. Just in case. Especially when adding one more item to an already exhaustive testing panel.

    That logic is how licensed cannabis markets end up buried under compliance layers copied from other states, calibrated to someone else's problems.

    It is also exactly how two adjacent markets with nearly identical consumer bases, Ohio and Michigan, ended up with completely different market structures.

    What they do not share is regulatory philosophy. When one state watches another add a rule and asks itself whether it should do the same, the answer it lands on shapes the entire cost structure of every licensed operator inside its borders. Ohio learned to ask the follow-up question. Most states never do.

    Ohio closed the intoxicating hemp loophole on March 20th, ahead of the federal government, and those shops are starting to close. The next unlock may already be here: THC beverages reaching the customers who will never walk into a dispensary, sold at the restaurant down the street.

    This week we sit down with Caroline Henry, VP of Government and Regulatory Affairs at Buckeye Relief.

    • The regulator FOMO problem
    • Ohio vs. Michigan: two markets, one lesson
    • THC beverages as the dispensary gateway

    Chapters

    00:00 The Disconnect in Cannabis Perception

    03:12 Navigating Stigma and Misconceptions

    05:48 Regulatory Challenges and Industry Standards

    08:55 Building Relationships with Regulators

    11:54 Small Wins in Regulatory Negotiations

    15:02 The Impact of Over-Regulation

    17:48 Child-Resistant Packaging and Its Irony

    25:38 Navigating Regulatory Challenges in the Cannabis Industry

    26:00 The Role of Beverages in Reducing Stigma

    30:37 Learning from Michigan: Ohio's Cannabis Strategy

    39:31 Focusing on Ohio: The Case for Local Expertise

    44:00 The Realities of Working in the Cannabis Industry

    Guest Links

    • www.buckeyerelief.com
    • www.amplifydispensary.com

    Our Links:

    Bryan Fields on Twitter

    The Dime on Twitter

    Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.

    At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

    The Dime is a top 5% most shared global podcast

    The Dime is a top 10 Cannabis Podcast

    The Dime has a New Website. Shhhh its not finished.

    🎥 YouTube: The Dime

    📸 Instagram: The Dime

    https://www.newton-insights.com/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    Cannabis Was Medicine. Now the Proof Is Catching Up, ft. Joel Stanley and Dr. Marcel Bonn-Miller May 21, 2026
    Show notes

    The cannabis industry convinced the world it had a medicine before the science caught up. Now the science is here, and almost no one is paying attention.

    CBD is not a panacea. When Charlotte's Web opened hearts and minds, the messaging of what it could do ran years ahead of what the data could actually support. That gap created a backlash the legitimate medical thesis didn't deserve. What's left on the other side of the green rush is a near-complete forgetting of the reason this industry started in the first place. The medicine. Now the infrastructure to prove it is finally in place. Standardized genetics. Reproducible extraction. Full compound characterization. An FDA botanical drug pathway that has existed since 2016 that most investors have never heard of. Organic medicine versus synthetic single-molecule will be a real choice at the pharmacy counter sooner than most people expect. The foundational work is already here.

    This week we sit down with Joel Stanley and Dr. Marcel Bonn-Miller:

    • Botanical drugs vs. supplements
    • 6,000 compounds, one drug
    • Novel compounds nobody has named yet

    Chapters

    00:00 Why Medical Validation Remains a Challenge for Cannabis

    00:12 The FDA Approval Process for Plant-Based Medicines

    01:03 Historical Market Dynamics and Their Impact on Cannabis Perception

    02:48 Removing the Veil: How Science Can Validate Cannabinoid Therapies

    03:15 The Complexity of Plant Molecules and Real-World Evidence

    06:20 Focus in Drug Development: The Case of Autism Spectrum Disorder

    07:10 The Impact of Charlotte's Web and Media Hype

    08:52 Balancing Hype and Reality in Cannabinoid Medicine

    10:01 Legitimization of Cannabis Research in Academia

    12:10 The Evolution of Cannabis Research and Acceptance

    13:54 The Future of Botanical Medicine and Academic Research

    16:15 The Long Road of Drug Development for Cannabis-Based Medicines

    20:50 Introducing AJA-001: A Botanical Drug for Autism

    22:44 Standardization and Characterization of Botanical Drugs

    24:01 Partnerships and Funding in Botanical Drug Development

    24:40 Challenges of Multi-Compound Botanical Drugs

    27:28 Reproducibility and Quality Control in Botanical Manufacturing

    29:06 FDA Pathways for Botanical Drugs and New Chemical Entities

    34:29 Identifying and Characterizing Thousands of Plant Compounds

    39:48 The Role of AI and Supercomputing in Drug Discovery

    41:11 Balancing Exploration and Focus in Botanical Research

    44:38 What the World Will Understand About Cannabinoids in 10 Years

    47:24 The Promise of Botanical Medicine Over Single Molecule Drugs

    Guest Links:

    AJNA Biosciences Website
    https://ajnabiosciences.com/

    AJNA Biosciences LinkedIn
    https://www.linkedin.com/company/ajna-biosciences/posts/?feedView=all

    AJNA Biosciences Instagram
    @ajnabiosciences

    Charlotte’s Web Website
    https://www.charlottesweb.com/

    Charlotte’s Web LinkedIn
    https://www.linkedin.com/company/charlottesweb/posts/?feedView=all

    Charlotte’s Web Instagram
    @charlotteswebcbd

    Joel Stanley LinkedIn
    https://www.linkedin.com/in/joel-stanley-2885116b/

    Joel Stanley Instagram
    @joel.stanley

    Dr. Marcel Bonn-Miller LinkedIn
    https://www.linkedin.com/in/marcel-bonn-miller-897a581/

    Our Links:

    Bryan Fields on Twitter

    Kellan Finney on Twitter

    The Dime on Twitter

    Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.

    At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

    The Dime is a top 5% most shared global podcast

    The Dime is a top 10 Cannabis Podcast

    The Dime has a New Website. Shhhh its not finished.

    🎥 YouTube: The Dime

    📸 Instagram: The Dime

    https://www.newton-insights.com/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    Joe Lustberg: What Cannabis Lenders See That Operators Miss May 15, 2026
    Show notes

    The number in your head and the number you actually need are not the same number. That gap is where most cannabis businesses break.

    Joe Lustberg has financed operators across the country for years and watched that gap swallow businesses that looked fine on paper. He has also spent over two years paying rent on a Hamptons dispensary he cannot open because a municipality tried to rezone his property out from under him. The person telling you to build in 1.5X as your burn capital cushion has been living inside exactly the scenario he warns everyone about.

    When the lender financing your industry has lived the same nightmare, the advice changes.

    This week we sit down with Joe Lustberg, to discuss the following

    • NY Regulatory Battlefield
    • 280E Gone: What Changes
    • Lending Specifics

    Chapters

    00:00 Navigating the Cannabis Landscape: A Personal Journey

    02:51 Understanding the Financial Risks in Cannabis Operations

    06:01 The Importance of Burn Capital for Cannabis Startups

    09:02 Lending Dynamics in the Cannabis Industry

    11:55 Market Trends and the Future of Cannabis Financing

    14:51 The Impact of Rescheduling on Cannabis Operators

    18:01 Identifying Strong Operators in a Competitive Market

    21:05 Evaluating Financial Health: Key Indicators for Success

    26:01 Evaluating Limited Markets: The Ohio Perspective

    28:24 Navigating Unique Financing Requests

    29:12 Surprising Success Stories in Cannabis Financing

    32:04 The Importance of Experience in New Ventures

    35:46 Identifying Undervalued Markets in Cannabis

    38:00 The Future of Cannabis Markets and Interstate Commerce

    Guest Links

    https://www.linkedin.com/in/joseph-lustberg-23076722

    Our Links:

    Bryan Fields on Twitter

    Kellan Finney on Twitter

    The Dime on Twitter

    Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.

    At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

    The Dime is a top 5% most shared global podcast

    The Dime is a top 10 Cannabis Podcast

    The Dime has a New Website. Shhhh its not finished.

    🎥 YouTube: The Dime

    📸 Instagram: The Dime

    https://www.newton-insights.com/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


    1 2 3 31 Next

    Related Podcasts

    How I Built This with Guy Raz

    1

    How I Built This with Guy Raz Business
    Planet Money

    2

    Planet Money Business
    Inside Strategic Coach: Connecting Entrepreneurs With What Really Matters

    3

    Inside Strategic Coach: Connecting Entrepreneurs With What Really Matters Business
    BiggerPockets Real Estate Podcast

    4

    BiggerPockets Real Estate Podcast Business
    The Smart Passive Income Online Business and Blogging Podcast

    5

    The Smart Passive Income Online Business and Blogging Podcast Business
    A Thousand Natural Shocks With Gabe S. Dunn

    6

    A Thousand Natural Shocks With Gabe S. Dunn Business
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights